Critical Care: Applying Genomics to Inflammation Outcomes by Schmidt, Charles W.
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Applying Genomics to
Inflammation Outcomes
Focus | Critical Care
What do gunshot wounds, burns, heart attacks, arthritis, asthma,
and cancer all share in common? Apart from inflicting misery,
these conditions—and others too—involve inflammation, an
immune response to injury and infection that normally protects,
but sometimes endangers or kills patients. Caused by immune cells
accumulating at a site of injury, inflammation typically guards
against infection and speeds recovery; it is a critical process and,
per se, does not cause disease. But unchecked inflammation that
spreads or fails to subside poses chronic and acute health risks for
millions of people. Asthma patients, for instance, can’t breathe
because inflammatory compounds cause airway linings to swell
and mucus to spread in the lungs. Inflammation also exacerbates
cancer, scientists believe, by facilitating the proliferation of abnor-
mal cells. An acute condition called sepsis—caused when infection
or inflammation spills into the bloodstream—produces organ fail-
ure and shock in critically ill patients. Up to 215,000 Americans
die from sepsis every year, according to the National Institute of
General Medical Sciences. Worldwide, sepsis is estimated to kill
1,400 people each day, according to a consensus document pub-
lished in the June 1992 issue of Chest. 
In light of its implications, inflammation has become one of
the hottest areas in biomedical research. J. Perren Cobb, a profes-
sor of surgery and genetics at Washington University in St. Louis,
says a wide array of medical specialties stand to benefit from these
investigations. “Inflammation is a major unifying syndrome, the
investigation of which provides opportunities for multidisciplinary
convergence,” he explains. “Studies of inflammation cut across all
the domains at the NIH; it’s a fundamental process in human biol-
ogy that ties everything together.”
Growing evidence suggests that genetic factors drive key
aspects of an individual’s inflammatory outcome. Scientists study-
ing inflammation are trying to identify the genes that drive inflam-
mation as well as biomarkers from throughout the course ofB
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inflammation. Stephen Chanock, who
heads the Section on Genomic Variation
in the Pediatric Oncology Branch at the
National Cancer Institute, emphasizes
that the current critical care orientation of
this research has broad multidisciplinary
implications that extend to environmental
health. “Injuries represent the ultimate
gene–environment interactions,” he
explains. “Usually environmental health
focuses on chronic exposures, but in this
case we’re studying environmental insults
that are more dangerous and intense. So,
the ‘environment’ in environmental
health isn’t just about pollution, it’s also
experiential. We’re developing practical
methods for looking at inflammation that
will ultimately be applied to larger public
health issues.”
Toward Better Knowledge of
Inflammation
Today, genomics defines the cutting edge
of inflammation research. Genomic stud-
ies, in addition to their proteomic and
metabolomic cousins, aim to resolve an
age-old mystery: namely, why some
patients recover readily from inflammation
while others suffer and die from it. The
current research emphasis focuses on criti-
cal care, particularly of trauma and burn
patients, who face the lethal dangers of
septic complications. Ideally, new gene-
based discoveries will provide diagnostic
biomarkers to predict who among these
patients will react poorly to inflammation
and why. If doctors could reliably predict
this outcome in advance, they might tailor
antibiotics and other treatment options to
a patient’s own inflammatory system,
potentially saving lives. 
Better knowledge of inflammation
biology could also spawn new treatment
options, Cobb says. The newest drug for
sepsis—an Eli Lilly and Company product
called Xigris that came on the market in
2001—helps some patients, but its cost is
exorbitant: nearly $7,000 per course of
treatment. What’s more, the drug reduces
the risk of death by just 6% and can pro-
duce side effects such as excessive bleeding. 
Among the numerous programs mov-
ing inflammation research forward is an
effort funded by a National Institute of
General Medical Sciences “glue grant,” so
named because it “glues together” multi-
disciplinary efforts to tackle biomedical
questions beyond the means of any one
research group. This program, called
Inflammation and the Host Response to
Injury, strives to determine why patients
can have dramatically different outcomes
after traumatic injuries and burns.
Headed by Ronald Tompkins, a professor
of surgery at Harvard Medical School and
chief of Massachusetts General Hospital’s
Burn Service, the program uses genomic
and proteomic methods to study inflam-
mation at 22 clinical centers located
throughout the country. A total of $37
million was made available for the pro-
gram’s first five years. 
When the Inflammation and Host
Response to Injury program was launched
in 2001, its leaders decided to create a
broad research infrastructure with uniform
protocols as a first priority. “One of our
first challenges was to develop guidelines,
not just for the sample collection and
analysis, but also for patient management,”
says Lyle Moldawer, a glue grant recipient
and professor of surgery at the University
of Florida College of Medicine. “We recog-
nized that all the funded centers have dif-
ferent protocols for the immediate care of
trauma and burn patients, and we were
concerned that those differences in early
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management might contribute to gene
expression changes.” 
Tompkins says creating a uniform
infrastructure for the program was like
building a highway. “We needed the gas
stations, the on-ramps, the off-ramps,” he
says. “No one had ever tried to introduce
this technology into critical care medicine
before.” With standard operating proce-
dures in place and the program now in its
fourth year, scientists have begun to
address a subsequent challenge: extracting
useful knowledge from the reams of
genomic data flowing out of the program’s
22 clinics.
At the same time the glue grant pro-
gram was gearing up, Cobb, senior inves-
tigator Anthony Suffredini of the NIH
Critical Care Medicine Department, and
Robert Danner, who heads the Infectious
Diseases Section in the same department,
created the Consortium for Expression
Profile Studies in Sepsis specifically to
identify the needs of those applying
genomic methods to critical care. The
consortium hosted four meetings
throughout the country before evolving
into the NIH Functional Genomics of
Critical Illness and Injury Symposia
series, which now provides a forum where
glue grant recipients and others discuss
research progress and results. The most
recent symposium, hosted by the NIH at
its Bethesda campus on 21–22 April
2005, was attended by scientists from 10
countries, all seeking to advance genomics
in inflammation research. 
An Inflammation Primer
Once triggered, inflammation proceeds
similarly whether caused by pollutants,
pathogens, trauma, radiation, or burns.
Localized mast cells in affected tissues pro-
duce histamine, a chemical mediator that
dilates blood vessels at the site of injury,
producing redness and heat. Histamine
also renders blood vessels permeable, so
leukocytes (white blood cells) can reach the
injury. Leukocytes are attracted to the
injury site by chemotactic proteins known
as chemokines, which are secreted by
endothelial cells of the blood vessels. 
Leukocytes originate in bone marrow
and include diverse cell types, such as neu-
trophils, eosinophils, basophils, mono-
cytes, lymphocytes, and macrophages.
Neutrophils arrive at the affected area
first. These remarkable cells roam the
body and kill pathogens on demand with
a toxic blend of free radicals and protein-
chewing enzymes that destroy bacterial
cell walls. Monocytes engulf cellular
debris and mature into macrophages,
which are larger leukocytes that consume
entire bacteria. These cells also secrete a
variety of cytokines that recruit and acti-
vate other cell types. Lymphocytes are
divided in two broad classes—B cells and
T cells—each with different roles. B cells,
once activated, make antibodies that
attack foreign substances, while T cells kill
infected cells directly. 
Chemical mediators released by leuko-
cytes during inflammation come in many
varieties. Cytokines, for instance, help to
regulate inflammation, whereas inter-
leukins regulate T cell activity and produce
systemic effects such as fever. 
Normally, the whole inflammation
process is self-limited and short-lived;
leukocytes disperse after dispensing with
infectious agents, and inflammation dies
down within hours or days. Problems crop
up when the response persists or spreads sys-
temically, damaging and killing normal tis-
sues in the process. Chronic inflammation
can persist for years, causing illnesses that
end with the suffix “-itis,” such as bronchi-
tis, arthritis, and bursitis. Systemic inflam-
mation—sepsis being one variety—occurs
when cytokines reach the bloodstream and
spread through the body, damaging organs
far from the initial injury’s source.
Candidate Genes
No one knows precisely what happens
when inflammation goes awry. Years of
immunology research have implicated
hundreds of genes in abnormal inflamma-
tion, but the evidence linking them to par-
ticular outcomes is weak. Of these genes,
the one coding for C-reactive protein
(CRP), an acute-phase molecule whose lev-
els shoot up during systemic inflammation,
is perhaps the best known. High CRP lev-
els are prognosticators for heart disease and
stroke (which are both linked to inflamma-
tion), but its role in these conditions
remains unclear. Another well-known
gene—tumor necrosis factor–alpha
(TNF-α)—codes for a pro-inflammatory
cytokine that normally regulates leukocyte
and endothelial cell activity, in addition to
other functions. 
By the 1990s, however, candidate gene
studies had yet to produce clinical benefits
for inflammation. Suffredini says scientists
at the time were extremely frustrated with
the lack of progress. “People were throwing
up their hands and feeling [painted] into
corners,” he says.
A turning point emerged at the turn of
the millennium, when a rough draft of the
human genome and the advent of microar-
rays made it possible to assess the expres-
sion of thousands of genes simultaneously.
“The analogy is that for years, we’d been
working on the ground to see how candi-
date genes interact,” Cobb explains. “But
microarrays allowed us to look down at the
genome from twenty thousand feet, so to
speak, and that has enabled us to model
much broader interactions.” 
With these tools, scientists could search
for entirely new genes and molecular path-
ways involved in disease processes. Cancer
researchers were among the first to exploit
the technology for clinical aims, Suffredini
says, inspiring their counterparts in critical
care to do the same. Thus, inflammation
research entered a new phase of gene dis-
covery that drives much of the progress in
the field today. Scientists are now investi-
gating a variation in the promoter region
of TNF-α (the region that initiates protein
production after binding transcription fac-
tors) that might contribute to sepsis.
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Injuries represent the ultimate gene–environment
interactions. Usually environmental health focuses
on chronic exposures, but in this case
we’re studying environmental insults 
that are more dangerous and intense.
–Stephen Chanock
National Cancer InstituteWhile cancer genomics inspired simi-
lar efforts in critical care, both specialties
operate under vastly different research set-
tings. For one thing, cancer patients typi-
cally have the time and awareness to pro-
vide informed consent for blood and tis-
sue sampling. In addition, the cohorts
tend to be large and matched for age, sex,
treatment history, and other parameters
that can influence genomic profiles.
Trauma and burn patients, on the other
hand, are rushed—often unconscious—
into the emergency room or intensive care
unit, where live-saving treatment is the
first priority. In this frenetic environment,
informed consent is difficult to secure,
and research sampling becomes a second-
ary concern. 
Moreover, cancer and trauma induce
totally different types of gene expression—
whereas tumors typically produce localized,
stable expression profiles corresponding to
small portions of the genome, critical
injuries trigger enormous genomic changes
that affect all tissues and shift rapidly over
time. Temporal factors are extremely
important in critical care sampling because
they have a tremendous influence on the
gene profile; a sample taken 15 minutes
after injury will be vastly different than one
taken several hours later. 
Into the Data
According to Tompkins, investigators with
the glue grant program chose to investi-
gate normal and abnormal inflammation
trajectories sequentially, each in five-year
increments. Genomic and proteomic data
for the normal trajectory—compiled using
samples from trauma and burn patients
who recovered uneventfully—are now
being analyzed. 
At the same time, program scientists
augmented the clinical research with
additional genomewide expression studies
of leukocytes sampled from healthy vol-
unteers dosed intravenously with bacteri-
al endotoxin. These studies—which
induced low-level systemic inflammation
that permitted validation of sample pro-
cessing protocols—enabled scientists to
compare baseline and inflammatory
genomic changes at varying time points.
Patients weren’t harmed by the experi-
ments, and all responses returned to nor-
mal within 24 hours. 
The results, published in the 31
August 2005 issue of Nature, showed how
complex inflammatory networks really
are—between 3,000 and 5,000 genes, up
to 20% of the entire genome, were acti-
vated, according to Moldawer, one of the
study’s authors. “The research revealed
that the magnitude of the changes was
much larger than we anticipated,” he says.
“We expected to see up-regulation of
stress-related genes during the acute phase,
but much to our surprise, the diversity of
the changes was much greater than we
thought it would be.” 
Many of those changes, Moldawer
adds, were seen in genes involved in mito-
chondrial energy transfer, protein synthesis,
and antigen recognition—in short, biologi-
cal processes that enable leukocytes to
become more efficient antimicrobial
agents, he says. Preliminary analyses sug-
gested the magnitude and nature of the
endotoxin response shared some similarities
with the response seen in real patients. At
press time, the clinical data from actual
patient cohorts were still being assessed. 
Although the amounts of genomic data
may be computationally daunting, recent
evidence from another study suggests
efforts to distinguish good inflammatory
outcomes from bad might have promise.
This study, published in the 29 March
2005 Proceedings of the National Academy of
Sciences, made several key discoveries. First,
hospitalization and repeated sampling had
only a modest effect on gene expression in
healthy volunteers. Thus, the experience of
being hospitalized (with its enforced bed
rest and defined nutritional intake) is
unlikely to influence gene expression in
ways that undermine the detection of sig-
nature profiles for specific inflammatory
outcomes. Second, the researchers showed
that gene expression differences in whole-
blood leukocytes drawn from severe trau-
ma patients could be divided into
injury-specific patterns. Taken together,
says coauthor Tompkins, the findings indi-
cate that expression profiling may yield
“low-hanging fruit” in the form of highly
correlated data. 
Linking Sepsis-Related Genes to
Biology
Meanwhile, researchers in Germany have
shown that subsets of genes can be linked
directly to sepsis. Among these researchers is
Trinad Chakraborty, who directs the
Institute of Medical Microbiology at Justus-
Liebig University. Chakraborty is complet-
ing a study of genomic factors contributing
to sepsis in patients with multiple trauma or
pneumonia. The study—part of a broader
effort to understand
why patient outcomes
differ after similar
injuries and illness-
es—involved screen-
ing up to 20,000
genes in peripheral
blood during a 14-day
post-injury period.
The effort, conducted
in 185 patients, found
690 genes whose
expression appears to
correlate with sepsis.
In future research,
Chakraborty plans to look for single-
nucleotide polymorphisms within candidate
genes that predispose the sepsis phenotype,
and to identify protein-based biomarkers
for diagnostic use. 
But Chakraborty adds that computa-
tional challenges are a serious holdup.
“When we started the research, getting the
microarrays to be sufficiently robust was the
bottleneck,” he says. “Now we’ve resolved
that problem, and bioinformatics is the bot-
tleneck.” He and his colleagues hope to trim
the 690 genes to a lesser population of 25 or
so. “Then we could develop an algorithm
that recognizes a profile within that smaller
set of genes to indicate whether you have a
likelihood of sepsis or not.”
U.S. scientists have also correlated
genes with sepsis and used these findings
to suggest a preliminary mechanism for its
lethality. Led by Hector Wong, who
directs the Division of Critical Care
Medicine at Cincinnati Children’s
Hospital Medical Center, the scientists
used microarrays to compare gene profiles
between children who survived sepsis and
those who died from it. Children respond
uniquely to sepsis in that their fatality
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Inflammation is a major unifying syndrome,
the investigation of which provides opportunities
for multidisciplinary convergence. . . .
It’s a fundamental process in
human biology that ties everything together.
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rates are much lower than those of
adults—roughly 10% compared to 30%
among the latter, says Chanock. 
Wong suspects that children respond
better to sepsis in part because they have
fewer comorbidities such as diabetes and
heart disease (a status that is changing
somewhat with rising childhood obesity).
But he further suspects genetic factors
underlie important biological differences
that improve their outcomes, though at
this point he can’t say how. 
In recent studies presented at the April
symposium, Wong found that among non-
surviving children, six genes coding for
metallothionein—a protein that binds zinc
and removes it from the bloodstream—
appeared to be highly expressed. These
findings led him to a hypothesis: if severe-
ly septic children had high blood metal-
lothionein levels, he proposed, then their
blood zinc levels might be correspondingly
low. “And in fact, that turned out to be
true,” he says. 
Another interesting finding was that
the profiles showed altered expression pat-
terns for a host of proteins that either
depend on zinc or take part in zinc home-
ostasis. “So there’s a lot of biology there to
look at,” Wong says. “We don’t know how
or whether zinc is involved; there’s very lit-
tle information out there about the effects
of acute zinc deficiency. I find it hard to
believe the foundation for sepsis is zinc,
but . . . I think it can be tested.” After con-
sidering this position further, Wong adds
that this is how high-throughput investiga-
tions are useful: they suggest biological
mechanisms that scientists can explore fur-
ther in the laboratory.
Future Needs
Today, a genomic research culture is slowly
seeping into the front lines of care for the
critically ill and injured. But establishing
that culture isn’t easy—emergency room
and intensive care unit settings challenge
researchers in many ways. Issues like
informed consent for study participation
and repeated intrusive blood sampling to
assess temporal changes in the genome are
difficult to manage, Tompkins says. Ideally,
new technologies will reduce sample vol-
ume requirements, lessen the amount of
time required for microarray analysis
(which now averages 24 hours), and reduce
microarray costs to the extent that they can
be used routinely in the clinic. 
Chakraborty adds that microarray plat-
forms need to accommodate sample degra-
dation too. As it stands now, he says, RNA in
blood samples drawn in the emergency room
has a higher degradation potential than
RNA in samples drawn from the more con-
trolled environment of a research laboratory.
“The platforms need to become more
robust,” Chakraborty says. “That way, if the
quality of the RNA drops to fifty or seventy
percent rather than a hundred percent, we
would still be able to get meaningful results.”
Researchers with the glue grant program are
also seeking to set up guidelines for stan-
dardized research procedures that will help
lessen the potential for sample degradation. 
Inflammation genomics also poses enor-
mous computational challenges. Studies
that lack sufficient statistical rigor are a per-
sistent problem, Cobb says—emergency
room and intensive care unit cohorts tend to
be smaller than optimal, and patients come
in after the trauma has occurred so they
can’t serve as their own controls. At the same
time, lists of inflammation-specific genes
identified during microarray experiments
need to be incorporated into biological
models that describe their molecular inter-
actions. Bioinformatic research and associat-
ed databases are continually advancing to
meet these needs, however, and collabora-
tions among research groups both within
the United States and abroad are helping to
drive the science forward. 
Cobb emphasizes that despite its broad
public health impact, inflammation
research has yet to achieve the same public
awareness as that of cancer or heart disease.
“We need to do a better job of educating
people about the importance of this
process,” he says. This means reaching
other scientists as well as the public, whose
concerns often drive research funding.
In the meantime, genomic methods
have generated incremental advances in our
understanding of inflammation. Scientists
have barely scratched the surface of its vast
complexity, but perhaps in the not-too-dis-
tant future, patients will reap the benefits of
their efforts.
Charles W. Schmidt
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We need to do
a better job
of educating people
about the importance
of this process.
–J. Perren Cobb 
Washington University in St. Louis 
Small advances. Fatality rates from sepsis are much lower in children than adults, so much may be learned
from how children’s bodies deal with inflammation.